Phase II study of weekly docetaxel in patients with metastatic breast cancer
Authors:
Open Access
- 20 February 2002
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 13 (2) , 286-292
Abstract
Background This study was conducted to investigate the efficacy and toxicity of weekly docetaxel administration in patients with metastatic breast cancer. Patients and methods Thirty-seven women were treated with 1 h infusions of docetaxel at 40 mg/m2/week after pre-medication with 8 mg dexamethazone. Each cycle consisted of three consecutive weekly treatments followed by a 1 week rest. All patients were assessed for toxicity; five patients were not assessable for clinical response, time to progression (TTP) and overall survival (OS) because of early treatment failure, but they were included in intention-to-treat analysis. Results Patients received a median of four cycles (range, 1–9), with a median dose intensity of 28 mg/m2/week (range 22–30) and a median relative dose intensity of 0.95 (range 0.73–1.0). No patients showed complete response, whereas 14 had partial response, which accounted for 38% of objective response rate [95% confidence interval (CI) 22% to 53%]. In addition, three patients (8%, 95% CI 0% to 17%) had stable disease over 6 months. Clinical responses were achieved at a median of three cycles (range 1–4 cycles). The median TTP and OS were 5 and 12 months, respectively. The weekly docetaxel regimen was generally well tolerated. About half of the patients experienced grade ≥1 neutropenia; only 19% had grade 3/4 neutropenia, including one case of grade 4. No febrile neutropenia was observed and fluid retention syndrome was uncommon. Non-hematologic toxicity, however, such as asthenia/fatigue, nail damage, tearing or hearing disorders, was seen with successive treatment cycles. Conclusions Weekly docetaxel at 40 mg/m2/week is an active and feasible regimen for patients with metastatic breast cancer.Keywords
This publication has 17 references indexed in Scilit:
- Docetaxel Administered on a Weekly Basis for Metastatic Breast CancerJournal of Clinical Oncology, 2000
- Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer PatientsJournal of Clinical Oncology, 2000
- Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patientsEuropean Journal of Cancer, 1999
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.Journal of Clinical Oncology, 1998
- Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.Journal of Clinical Oncology, 1996
- A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTCAnnals of Oncology, 1996
- Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.Journal of Clinical Oncology, 1995
- Early clinical studies with docetaxelEuropean Journal of Cancer, 1995
- Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.Journal of Clinical Oncology, 1995